Financial reports
10-Q
2020 Q3
Quarterly report
6 Nov 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
10-Q
2020 Q1
Quarterly report
11 May 20
10-K
2019 FY
Annual report
16 Mar 20
10-Q
2019 Q3
Quarterly report
13 Nov 19
10-Q
2019 Q2
Quarterly report
14 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19
10-K
2018 FY
Annual report
26 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
10-Q
2018 Q2
Quarterly report
14 Aug 18
Current reports
8-K
Liquidia Closes Acquisition of RareGen
18 Nov 20
8-K
Liquidia Announces Results of Special Meeting of Stockholders
16 Nov 20
8-K
Liquidia Reports Third Quarter 2020 Financial Results and Provides Corporate Update
9 Nov 20
8-K
Liquidia Reschedules Special Meeting of Stockholders and Reaffirms Recommendation to Approve Proposed Acquisition of RareGen, LLC
2 Nov 20
8-K
Liquidia Announces Postponement of Special Meeting of Stockholders
19 Oct 20
8-K
Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics’ Tyvaso® Patents
14 Oct 20
8-K
Liquidia Announces Chief Financial Officer Transition
20 Aug 20
8-K
Liquidia Reports Second Quarter 2020 Financial Results and Provides Corporate Update
10 Aug 20
8-K
Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent
24 Jul 20
8-K
Liquidia Announces Proposed Offering of Common Stock
2 Jul 20
Registration and prospectus
15-12B
Securities registration termination
30 Nov 20
25-NSE
Exchange delisting
18 Nov 20
POS AM
Prospectus update (post-effective amendment)
18 Nov 20
POS AM
Prospectus update (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
425
Business combination disclosure
16 Nov 20
425
Business combination disclosure
9 Nov 20
Proxies
DEFA14A
Additional proxy soliciting materials
5 Nov 20
DEFA14A
Additional proxy soliciting materials
2 Nov 20
DEFA14A
Additional proxy soliciting materials
19 Oct 20
DEFA14A
Additional proxy soliciting materials
8 Oct 20
DEFA14A
Additional proxy soliciting materials
18 Sep 20
DEFA14A
Additional proxy soliciting materials
17 Sep 20
DEFM14A
Proxy related to merger
17 Sep 20
DEFA14A
Additional proxy soliciting materials
20 Aug 20
DEFA14A
Additional proxy soliciting materials
10 Aug 20
DEFA14A
Additional proxy soliciting materials
29 Jun 20
Other
EFFECT
Notice of effectiveness
23 Nov 20
EFFECT
Notice of effectiveness
23 Nov 20
SEC STAFF
SEC staff action: Order
23 Mar 20
SEC STAFF
SEC staff action: Order
2 Mar 20
EFFECT
Notice of effectiveness
14 Feb 20
CORRESP
Correspondence with SEC
11 Feb 20
UPLOAD
Letter from SEC
11 Feb 20
EFFECT
Notice of effectiveness
11 Sep 19
EFFECT
Notice of effectiveness
21 Mar 19
CORRESP
Correspondence with SEC
18 Mar 19
Ownership
SC 13G/A
ArrowMark Colorado Holdings LLC
16 Feb 21
4
FREDRIC N ESHELMAN
27 Nov 20
4
FREDRIC N ESHELMAN
25 Nov 20
4
FREDRIC N ESHELMAN
24 Nov 20
4
FREDRIC N ESHELMAN
20 Nov 20
144
Notice of proposed sale of securities
20 Nov 20
3
Steven Bariahtaris
21 Aug 20
SC 13D/A
New Enterprise Associates 12, Limited Partnership
7 Jul 20
4
FREDRIC N ESHELMAN
2 Jul 20
4
Stephen M Bloch
23 Jun 20